US Stock MarketDetailed Quotes
OPT Opthea
Watchlist
2.630
+0.051+1.99% Close 12/06 16:00 ET
2.6300.0000.00%
Post 16:56 ET
2.650High2.510Low4.92KVolume
2.580Open2.579Pre Close12.63KTurnover0.01%Turnover RatioLossP/E (TTM)217.90MMarket Cap6.09052wk HighLossP/E (Static)82.85MShares1.60052wk Low-37.04P/B150.69MFloat Cap16.230Historical High--Dividend TTM57.30MShs Float1.600Historical Low--Div YieldTTM5.43%Amplitude2.567Avg Price1Lot Size
About Opthea Company
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It focuses on treating neovascular age-related macular degeneration and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984, and is headquartered in South Yarra, Australia.
Company Profile
SymbolOPT
Company NameOpthea
Issue Price13.50
Founded1984
CEODr. Megan Baldwin
MarketNASDAQ
Securities TypeDR
ADS Ratio1.0 : 8.0
Fiscal Year Ends06-30
Address650 Chapel Street,Suite 0403,Level 4
CitySouth Yarra
ProvinceVictoria (VIC)
CountryAustralia
Zip Code3141
Phone61-3-9826-0399
Websitehttp://www.opthea.com
Company Executives
- Name
- Position
- Salary
- Dr. Megan Baldwin
- Director, Chief Executive Officer and Managing Director
- 1.22M
- Timothy E. Morris
- Chief Financial Officer
- --
- Judith J. Robertson
- Chief Commercial Officer
- 502.06K
- Karen Adams
- Vice President, Finance and Company Secretary
- 379.27K
- Mark O Neill
- Vice President, Chemistry, Manufacturing and Controls
- --
- Bruno Gagnon
- Senior Vice President, Global Clinical Operations
- --
- Jeremy M. Levin, D.Phil.
- Chairman of the Board
- 933.29K
- Dr. Julia A. Haller, M.D.
- Director
- 642.69K
- Anshul Thakral
- Director
- --
- Dr. Ian Leitch
- Director of Clinical Research
- --
- Daniel K. Spiegelman
- Independent Director
- 771.22K
- Lawrence B. Gozlan
- Independent Director
- 656.47K
- Susan Orr
- Independent Director
- 137.59K
- Quinton Oswald
- Independent Director
- 137.59K
- Dr. Michael Gerometta
- Head of Chemistry, Manufacturing and Controls Development
- --
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--